Figure 6: Gene expression profile.

(A,B) Subcellular localization pattern of fantom3_F730004F19 by RNA FISH staining. A significantly higher expression of fantom3_F730004F19 in treated BV-2 microglia cells was estimated, and fantom3_F730004F19 was predominantly expressed in the nucleus. (C) Cellular localization pattern of fantom3_F730004F19 by qRT-PCR. Although there was no statistical difference between BV2 and HT22 cells, the level of fantom3_F730004F19 present a higher in BV2 cell line, lesser extent in HT22 cells and MOPC cells, and not detected in MA cells. (D) Comparison between sequencing and qRT-PCR analysis of 5 randomly selected lncRNAs. Positive values refer to upregulation, and negative values refer to downregulation. β-actin was used to normalize the expression of samples. Red representes RNA-seq data, and blue representes qRT-PCR. The bars represent standard error of the mean (SEM). The qRT-PCR results were closely correlated with the sequencing data (P < 0.05). (E) The silencing efficiency of the lentivirused on fantom3_F730004F19 in BV-2 microglia cells. Lentivirus-50305 (KD1) and lentivirus-50307 (KD3) significantly inhibited fantom3_F730004F19 expression (P < 0.05 versus Blank group). (F) Inhibition of fantom3_F730004F19 reduced the expression of CD14 and TLR4 in BV-2 microglia cells following LPS treatment. The expression of fantom3_F730004F19, CD14 and TLR4 were overexpressed in BV-2 cells after LPS treatment. Knockdown of fantom3_F730004F19 abated the increase of CD14 and TLR4 in LPS-treated BV-2 cells. ^@P < 0.05 and ^@@P < 0.01; *P < 0.05 and **P < 0.01 versus the NC normal group; ^#P < 0.05 and ^##P < 0.01 versus the NC LPS-treated group. BV-2: mouse microglial cell line; HT22: mouse neuronal cell line; MA: mouse astrocyte cell line; MOPC: mouse oligodendrocyte precursor cell line; N: normal condition group; LPS: lipopolysaccharide treated; Blank: non-transfected cells; NC: negative control lentivirus transfected cells; KD: the lncRNA fantom3_F730004F19 lentivirus transfected cells.